| # | Pathway | Proteins |
|---|
| 1 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000016339, ENSAPLP00000014420 |
| 2 | Ribosome | ENSAPLP00000012634, ENSAPLP00000008212, ENSAPLP00000014148, ENSAPLP00000008818, ENSAPLP00000015662, ENSAPLP00000015793, ENSAPLP00000010033, ENSAPLP00000004439, ENSAPLP00000003372, ENSAPLP00000008154 |
| 3 | Tyrosine metabolism | ENSAPLP00000003758, ENSAPLP00000005038, ENSAPLP00000012915, ENSAPLP00000004066 |
| 4 | Phenylalanine metabolism | ENSAPLP00000003758, ENSAPLP00000005038, ENSAPLP00000004066 |
| 5 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000016339 |
| 6 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000005955, ENSAPLP00000009880 |
| 7 | Tight junction | ENSAPLP00000014910, ENSAPLP00000010282, ENSAPLP00000007261, ENSAPLP00000007172, ENSAPLP00000012466, ENSAPLP00000005955, ENSAPLP00000009880 |
| 8 | Malaria | ENSAPLP00000014751, ENSAPLP00000007488, ENSAPLP00000011743 |
| 9 | Phagosome | ENSAPLP00000011602, ENSAPLP00000014529, ENSAPLP00000014751, ENSAPLP00000003050, ENSAPLP00000010045, ENSAPLP00000015503, ENSAPLP00000009880 |
| 10 | Viral myocarditis | ENSAPLP00000014751, ENSAPLP00000004152, ENSAPLP00000003050, ENSAPLP00000009880 |
| 11 | Pathogenic Escherichia coli infection | ENSAPLP00000011602, ENSAPLP00000014529, ENSAPLP00000010045, ENSAPLP00000015503, ENSAPLP00000009880 |
| 12 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000012522, ENSAPLP00000004152, ENSAPLP00000003657, ENSAPLP00000003219, ENSAPLP00000009880 |
| 13 | Dilated cardiomyopathy | ENSAPLP00000012522, ENSAPLP00000004152, ENSAPLP00000003657, ENSAPLP00000003219, ENSAPLP00000009880 |
| 14 | beta-Alanine metabolism | ENSAPLP00000003758, ENSAPLP00000014321, ENSAPLP00000004066 |
| 15 | Gap junction | ENSAPLP00000011602, ENSAPLP00000014529, ENSAPLP00000010045, ENSAPLP00000015503 |
| 16 | Proteoglycans in cancer | ENSAPLP00000011483, ENSAPLP00000013972, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000004439, ENSAPLP00000009880 |
| 17 | Leukocyte transendothelial migration | ENSAPLP00000010282, ENSAPLP00000013972, ENSAPLP00000014751, ENSAPLP00000003050, ENSAPLP00000009880 |
| 18 | Regulation of actin cytoskeleton | ENSAPLP00000009727, ENSAPLP00000010282, ENSAPLP00000014751, ENSAPLP00000003050, ENSAPLP00000005955, ENSAPLP00000004998, ENSAPLP00000009880 |
| 19 | Hippo signaling pathway - fly | ENSAPLP00000003083, ENSAPLP00000012596, ENSAPLP00000009880 |
| 20 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000011483, ENSAPLP00000004168, ENSAPLP00000014751 |
| 21 | Glycine, serine and threonine metabolism | ENSAPLP00000003758, ENSAPLP00000004066 |
| 22 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000009880 |
| 23 | Legionellosis | ENSAPLP00000000447, ENSAPLP00000014751 |
| 24 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050, ENSAPLP00000012498 |
| 25 | Hippo signaling pathway | ENSAPLP00000003083, ENSAPLP00000014751, ENSAPLP00000009880 |
| 26 | HIF-1 signaling pathway | ENSAPLP00000015679, ENSAPLP00000004439, ENSAPLP00000003760 |
| 27 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000012522, ENSAPLP00000004152, ENSAPLP00000009880 |
| 28 | Adherens junction | ENSAPLP00000003052, ENSAPLP00000003050, ENSAPLP00000009880 |
| 29 | Focal adhesion | ENSAPLP00000010282, ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000009880 |
| 30 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000014751, ENSAPLP00000003050, ENSAPLP00000009880 |
| 31 | Propanoate metabolism | ENSAPLP00000014321, ENSAPLP00000014420 |
| 32 | Synthesis and degradation of ketone bodies | ENSAPLP00000014420 |
| 33 | Lysosome | ENSAPLP00000005099, ENSAPLP00000009330, ENSAPLP00000004168, ENSAPLP00000014590 |
| 34 | Natural killer cell mediated cytotoxicity | ENSAPLP00000014751, ENSAPLP00000003050 |
| 35 | Glyoxylate and dicarboxylate metabolism | ENSAPLP00000009730, ENSAPLP00000014420 |
| 36 | ECM-receptor interaction | ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000000534 |
| 37 | Cardiac muscle contraction | ENSAPLP00000003657, ENSAPLP00000003219 |
| 38 | Intestinal immune network for IgA production | ENSAPLP00000014324 |
| 39 | Proximal tubule bicarbonate reclamation | ENSAPLP00000009730 |
| 40 | PPAR signaling pathway | ENSAPLP00000005715, ENSAPLP00000003052 |
| 41 | Protein digestion and absorption | ENSAPLP00000011483, ENSAPLP00000012993 |
| 42 | Insulin signaling pathway | ENSAPLP00000003052, ENSAPLP00000004439, ENSAPLP00000010189 |
| 43 | Viral carcinogenesis | ENSAPLP00000003083, ENSAPLP00000003050, ENSAPLP00000001720, ENSAPLP00000004998 |
| 44 | Prion diseases (no map in kegg database) | ENSAPLP00000016323, ENSAPLP00000000447 |
| 45 | Neuroactive ligand-receptor interaction | ENSAPLP00000004168 |
| 46 | Primary immunodeficiency | ENSAPLP00000014324 |
| 47 | Dorso-ventral axis formation | ENSAPLP00000016323 |
| 48 | Terpenoid backbone biosynthesis | ENSAPLP00000014420 |
| 49 | Phototransduction - fly | ENSAPLP00000009880 |
| 50 | Pyruvate metabolism | ENSAPLP00000009730, ENSAPLP00000014420 |
| 51 | Cocaine addiction | ENSAPLP00000012915 |
| 52 | Renin-angiotensin system | ENSAPLP00000004168 |
| 53 | Bacterial invasion of epithelial cells | ENSAPLP00000005099, ENSAPLP00000003050, ENSAPLP00000009880 |
| 54 | MicroRNAs in cancer | ENSAPLP00000016323, ENSAPLP00000013972, ENSAPLP00000003219 |
| 55 | Regulation of lipolysis in adipocytes | ENSAPLP00000005715 |
| 56 | Bladder cancer | ENSAPLP00000013972 |
| 57 | Notch signaling pathway | ENSAPLP00000016323 |
| 58 | Platelet activation | ENSAPLP00000010282, ENSAPLP00000011483, ENSAPLP00000009880 |
| 59 | Porphyrin and chlorophyll metabolism | ENSAPLP00000007495 |
| 60 | Inositol phosphate metabolism | ENSAPLP00000014321 |
| 61 | African trypanosomiasis | ENSAPLP00000007488 |
| 62 | Thyroid hormone signaling pathway | ENSAPLP00000016323, ENSAPLP00000009880 |
| 63 | Estrogen signaling pathway | ENSAPLP00000000447, ENSAPLP00000013972 |
| 64 | Mineral absorption | ENSAPLP00000015679 |
| 65 | N-Glycan biosynthesis | ENSAPLP00000000660 |
| 66 | Metabolism of xenobiotics by cytochrome P450 | ENSAPLP00000005537 |
| 67 | Drug metabolism - cytochrome P450 | ENSAPLP00000005537 |
| 68 | Systemic lupus erythematosus | ENSAPLP00000004168, ENSAPLP00000001720 |
| 69 | Wnt signaling pathway | ENSAPLP00000002426, ENSAPLP00000003050 |
| 70 | Carbon metabolism (no map in kegg database) | ENSAPLP00000014321, ENSAPLP00000003760, ENSAPLP00000009730, ENSAPLP00000014420 |
| 71 | MAPK signaling pathway | ENSAPLP00000000447, ENSAPLP00000003050, ENSAPLP00000003837 |
| 72 | Valine, leucine and isoleucine degradation | ENSAPLP00000014321, ENSAPLP00000014420 |
| 73 | Fc gamma R-mediated phagocytosis | ENSAPLP00000003050, ENSAPLP00000004998 |
| 74 | Complement and coagulation cascades | ENSAPLP00000010484, ENSAPLP00000006069 |
| 75 | mTOR signaling pathway | ENSAPLP00000004439 |
| 76 | Butanoate metabolism | ENSAPLP00000014420 |
| 77 | Amphetamine addiction | ENSAPLP00000012915 |
| 78 | Fructose and mannose metabolism | ENSAPLP00000003760 |
| 79 | Influenza A | ENSAPLP00000000447, ENSAPLP00000009880 |
| 80 | Chemical carcinogenesis | ENSAPLP00000005537 |
| 81 | Leishmaniasis | ENSAPLP00000014751 |
| 82 | Colorectal cancer | ENSAPLP00000003050 |
| 83 | Alcoholism | ENSAPLP00000001720, ENSAPLP00000012915 |
| 84 | Tryptophan metabolism | ENSAPLP00000014420 |
| 85 | Prolactin signaling pathway | ENSAPLP00000012915 |
| 86 | Pancreatic cancer | ENSAPLP00000003050 |
| 87 | Staphylococcus aureus infection | ENSAPLP00000014751 |
| 88 | PI3K-Akt signaling pathway | ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000004439 |
| 89 | Starch and sucrose metabolism | ENSAPLP00000010189 |
| 90 | VEGF signaling pathway | ENSAPLP00000003050 |
| 91 | Rheumatoid arthritis | ENSAPLP00000014751 |
| 92 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000003657, ENSAPLP00000003219 |
| 93 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 94 | Lysine degradation | ENSAPLP00000014420 |
| 95 | Vasopressin-regulated water reabsorption | ENSAPLP00000010780 |
| 96 | Endocytosis | ENSAPLP00000000447, ENSAPLP00000005099, ENSAPLP00000005705, ENSAPLP00000010780, ENSAPLP00000014479 |
| 97 | Pertussis | ENSAPLP00000014751 |
| 98 | Cysteine and methionine metabolism | ENSAPLP00000009730 |
| 99 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000005099 |
| 100 | B cell receptor signaling pathway | ENSAPLP00000003050 |
| 101 | Pancreatic secretion | ENSAPLP00000003050 |
| 102 | Ras signaling pathway | ENSAPLP00000003083, ENSAPLP00000003050 |
| 103 | Transcriptional misregulation in cancer | ENSAPLP00000013972 |
| 104 | TNF signaling pathway | ENSAPLP00000013972 |
| 105 | Pentose phosphate pathway | ENSAPLP00000003760 |
| 106 | Choline metabolism in cancer | ENSAPLP00000003050 |
| 107 | Renal cell carcinoma | ENSAPLP00000003050 |
| 108 | Ribosome biogenesis in eukaryotes | ENSAPLP00000006775 |
| 109 | Glutathione metabolism | ENSAPLP00000005537 |
| 110 | Fc epsilon RI signaling pathway | ENSAPLP00000003050 |
| 111 | Vibrio cholerae infection | ENSAPLP00000009880 |
| 112 | Prostate cancer (no map in kegg database) | ENSAPLP00000005537 |
| 113 | Salivary secretion | ENSAPLP00000009817 |
| 114 | Aminoacyl-tRNA biosynthesis | ENSAPLP00000007912 |
| 115 | Arginine and proline metabolism | ENSAPLP00000010692 |
| 116 | Synaptic vesicle cycle | ENSAPLP00000005099 |
| 117 | Measles | ENSAPLP00000000447 |
| 118 | Pyrimidine metabolism | ENSAPLP00000010112 |
| 119 | Antigen processing and presentation | ENSAPLP00000000447 |
| 120 | Gastric acid secretion (no map in kegg database) | ENSAPLP00000009880 |
| 121 | Citrate cycle (TCA cycle) | ENSAPLP00000009730 |
| 122 | Insulin resistance | ENSAPLP00000010189 |
| 123 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 124 | Fatty acid metabolism (no map in kegg database) | ENSAPLP00000014420 |
| 125 | Osteoclast differentiation | ENSAPLP00000003050 |
| 126 | Fatty acid degradation | ENSAPLP00000014420 |
| 127 | Cell adhesion molecules (CAMs) | ENSAPLP00000014751 |
| 128 | Glucagon signaling pathway | ENSAPLP00000010189 |
| 129 | Sphingolipid signaling pathway | ENSAPLP00000003050 |
| 130 | Parkinson's disease | ENSAPLP00000012915, ENSAPLP00000009038 |
| 131 | Alzheimer's disease | ENSAPLP00000011743, ENSAPLP00000009038 |
| 132 | AMPK signaling pathway | ENSAPLP00000010780 |
| 133 | Glycolysis / Gluconeogenesis | ENSAPLP00000003760 |
| 134 | Protein processing in endoplasmic reticulum | ENSAPLP00000000447, ENSAPLP00000011000 |
| 135 | Hepatitis B | ENSAPLP00000013972 |
| 136 | Vascular smooth muscle contraction (no map in kegg database) | ENSAPLP00000005955 |
| 137 | Toxoplasmosis | ENSAPLP00000000447 |
| 138 | cAMP signaling pathway | ENSAPLP00000003050 |
| 139 | Neurotrophin signaling pathway | ENSAPLP00000003050 |
| 140 | Axon guidance | ENSAPLP00000003050 |
| 141 | Dopaminergic synapse | ENSAPLP00000012915 |
| 142 | Spliceosome | ENSAPLP00000012296, ENSAPLP00000000447 |
| 143 | Tuberculosis | ENSAPLP00000014751 |
| 144 | Oxytocin signaling pathway | ENSAPLP00000009880 |
| 145 | Biosynthesis of amino acids (no map in kegg database) | ENSAPLP00000003760 |
| 146 | Herpes simplex infection | ENSAPLP00000012296 |
| 147 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000003050 |
| 148 | Chemokine signaling pathway | ENSAPLP00000003050 |
| 149 | Huntington's disease | ENSAPLP00000005099, ENSAPLP00000009038 |
| 150 | Pathways in cancer | ENSAPLP00000005537, ENSAPLP00000013972, ENSAPLP00000003050 |
| 151 | HTLV-I infection | ENSAPLP00000014751 |
| 152 | Metabolic pathways (no map in kegg database) | ENSAPLP00000010112, ENSAPLP00000000660, ENSAPLP00000003758, ENSAPLP00000014321, ENSAPLP00000003760, ENSAPLP00000010189, ENSAPLP00000009730, ENSAPLP00000010692, ENSAPLP00000012915, ENSAPLP00000004066, ENSAPLP00000014420, ENSAPLP00000009038 |
| 153 | Oxidative phosphorylation | ENSAPLP00000009038 |
| 154 | Epstein-Barr virus infection | ENSAPLP00000000447 |
| 155 | RNA transport | ENSAPLP00000008645 |